Over the last fifty years Parnell has become a leading global veterinary pharmaceutical business marketing products in 15 countries. We have built a fully integrated animal health platform with a strong track record in R&D, clinical science, regulatory processes and with recent FDA accreditation of our sterile manufacturing facility in Sydney, Australia we can bring innovative solutions to market swiftly. Parnell has also developed unique digital technology solutions that integrate with our innovative products to offer veterinarians and animal owners superior solutions to their animal health needs.
Parnell has a market-leading portfolio of products for companion, performance and production animals. We currently market innovative cattle breeding programs as well as osteoarthritis solutions for dogs and horses. In addition we have an impressive pipeline spanning anesthesia, anti-microbials, orthopedics and laminitis.
ZYDAX®, GLYDE® and TERGIVE® make up Parnell’s joint care program for dogs. Osteoarthritis can greatly affect the quality of life of your dog. Parnell’s premium suite of products are designed to protect against the painful and debilitating effects of osteoarthritis.
Parnell launched the first FDA-approved products for the synchronization of estrous cycles in lactating dairy cows and beef cows; GONAbreed® (gonadorelin acetate), in combination with estroPLAN® (cloprostenol sodium), can be used safely and effectively in various timed breeding programs.
In the racing industry, degenerative joint disease (DJD) is one of the biggest contributors to poor athletic performance. DJD prevents equine athletes achieving their maximum potential. Parnell has developed two products ZYDAX® and GLYDE® that modulate cartilage metabolism and reduce inflammation so you can meet your one objective…winning!